Trial Search Results

Temsirolimus to Reverse Androgen Insensitivity for Castration-resistant Prostate Cancer

This study evaluates if temsirolimus causes a reduction in the serum levels of prostate-specific antigen (PSA) in male subjects with castration-resistant prostate cancer (CRPC).

Stanford is currently not accepting patients for this trial.

Stanford Investigator(s):

Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Denise Haas
6507361252
Not Recruiting